
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc. reported a net loss of $9.7 million, equivalent to ($0.32) per share, which was better than the previously estimated loss of $10.6 million. This reflects improved financial performance relative to expectations, indicating effective cost management and operational efficiencies. The company's focus on developing low-cost diagnostic systems and reagents for a range of infectious diseases positions it favorably within the molecular diagnostics market.
Bears say
Co-Diagnostics Inc. reported total revenue of $0.6 million for the period, reflecting a substantial year-over-year decline of 74%, despite exceeding projections of $0.4 million. The company faced significant challenges, including a net loss of $9.7 million in 3Q24 and risks tied to lower product uptake, regulatory compliance issues, and the potential inability to develop additional infectious disease-related products. Such financial setbacks and operational uncertainties contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares